MAX-10181 Given Orally to Patients With Advanced Solid Tumor
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, first-in-human, non-randomized, open-label, single-arm,
dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in
patients with advanced solid tumor.